Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback